Pharmacogenetic Approach to Toxicity in Breast Cancer Patients Treated with Taxanes

被引：11
|
作者：
Angelini, Silvia [1 ,2 ]
Botticelli, Andrea [1 ]
Onesti, Concetta Elisa [1 ,2 ]
Giusti, Raffaele [2 ]
Sini, Valentina [1 ,3 ]
Durante, Valeria [1 ,2 ]
Strigari, Lidia [4 ]
Gentile, Giovanna [5 ]
Cerbelli, Bruna [6 ]
Pellegrini, Patrizia [2 ]
Sgroi, Valentina [1 ,2 ]
Occhipinti, Mario [1 ,2 ]
Di Pietro, Francesca Romana [1 ,2 ]
Rossi, Alessandro [7 ]
Simmaco, Maurizio [8 ]
Mazzuca, Federica [1 ,2 ]
Marchetti, Paolo [1 ,2 ,5 ]
机构：
[1] Sapienza Univ Rome, Dept Clin & Mol Med, Rome, Italy
[2] St Andrea Hosp, Dept Med Oncol, Via Grottarossa 1035, I-00189 Rome, Italy
[3] Santo Spirito Hosp, Rome, Italy
[4] Regina Elena Inst Canc Res, Lab Med Phys & Expert Syst, Rome, Italy
[5] Immacolata IDI IRCSS, Dermopat Inst, Rome, Italy
[6] Sapienza Univ Rome, Dept Radiol Oncol & Pathol Sci, Rome, Italy
[7] Sapienza Univ Rome, Fac Med & Psychol, Rome, Italy
[8] Sapienza Univ Rome, Dept Neurosci Mental Hlth & Sensory Organs NESMOS, Rome, Italy
来源：
ANTICANCER RESEARCH | 2017年 / 37卷 / 05期
关键词：
Breast cancer; taxanes; polymorphisms; ABCB1; P-gp; cytochrome P450; GENETIC POLYMORPHISMS; PERIPHERAL NEUROPATHY; RANDOMIZED-TRIAL; OVARIAN-CANCER; HUMAN LIVER; PACLITAXEL; ABCB1; DOCETAXEL; EXPRESSION; CHEMOTHERAPY;
D O I：
10.21873/anticanres.11610
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background: Taxanes are widely used to treat breast cancer patients. Taxanes are metabolized in human liver by the cytochrome CYP3A and are substrate of ATP-binding cassette multidrug transporters ABCB1. Single-nucleotide polymorphisms (SNPs) in genes involved in taxanes' metabolism could affect the inter-individual variability in reported toxicities. Materials and Methods: In this retrospective study, 152 women, affected by breast cancer and receiving a taxane-based chemotherapy, were enrolled. A peripheral blood sample was taken for genotyping the following polymorphisms: CYP3A4* 1B (A>G), CYP3A5 * 3 (G>A) and ABCB1 (C1236T; C3435T). Results: We observed an association between ABCB1 3435 T/T and lower grade of toxicities (p=0.05). No other association were found for CYP 3A4 * 1B, 3A5*3 and ABCB1 C1236T. Conclusion: ABCB1 3435 T/T seems to be associated to lower rate of toxicity in patients receiving taxanes. Further prospective and larger studies should be performed to clarify the role of this polymorphism.
引用
收藏
页码：2633 / 2639
页数：7
相关论文
共 50 条
  • [31] Pharmacogenetic study in patients (pts) with metastatic breast (BC) and colorectal cancer (CRC) treated with Capecitabine (C).
    Ribelles, N
    Sánchez, A
    Siles, JL
    González, E
    Sánchez, MJ
    Carabantes, F
    Rovira, PS
    Márquez, A
    Sevilla, I
    Alba, E
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 136S - 136S
  • [32] Pharmacogenetic study in patients (pts) with metastatic breast (MBC) and colorectal cancer (MCRC) treated with capecitabine (C)
    Alba, E.
    Ribelles, N.
    Sanchez, A.
    Lopez Siles, J.
    Sanchez, M. J.
    Gonzalez, E.
    Carabantes, F.
    Sanchez Rovira, P.
    Marquez, A.
    Sevilla, I.
    EJC SUPPLEMENTS, 2005, 3 (02): : 66 - 66
  • [33] HER2 as a prognostic factor in metastatic breast cancer treated with taxanes
    Parkes, E.
    McKenna, S. M.
    McAleer, J. J.
    Clarke, J.
    Clayton, A. J.
    James, C. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [34] Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes
    Luca Gianni
    Emanuela Salvatorelli
    Giorgio Minotti
    Cardiovascular Toxicology, 2007, 7 : 67 - 71
  • [35] Managing Patients With Advanced and Metastatic Breast Cancer: Taxanes and Epothilones
    Hurtig, Jane
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2010, 14 (03) : 313 - 323
  • [36] Cross-sensitivity between taxanes in patients with breast cancer
    Alfonso Sánchez-Muñoz
    Begoña Jiménez
    Ana García-Tapiador
    Gema Romero-García
    Laura Medina
    Víctor Navarro
    Luis Alonso González-Sánchez
    Emilio Alba
    Clinical and Translational Oncology, 2011, 13 : 904 - 906
  • [37] Cross-sensitivity between taxanes in patients with breast cancer
    Sanchez-Munoz, Alfonso
    Jimenez, Begona
    Garcia-Tapiador, Ana
    Romero-Garcia, Gema
    Medina, Laura
    Navarro, Victor
    Gonzalez-Sanchez, Luis Alonso
    Alba, Emilio
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2011, 13 (12): : 904 - 906
  • [38] The effect of obesity on prognosis in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathologic subtypes
    Pollan, Marina
    Pajares, Bella
    Martin, Miguel
    Mackey, John Robert
    Lluch, Ana
    Gavila, Joaquin
    Vogel, Charles L.
    Ruiz Borrego, Manuel
    Calve, Lourdes
    Pienkowski, Tadeusz
    Rodriguez-Lescure, Alvaro
    Angel Segui, Miguel
    Tredan, Olivier
    Anton, Antonio
    Ramos Vazquez, Manuel
    Carmen Camara, M.
    Rodriguez-Martin, Cesar
    Maria Carrasco, Eva
    Alba, Emilio
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [39] A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes
    Campone, M.
    Isambert, N.
    Bourbouloux, E.
    Roche, H.
    Bonneterre, J.
    Milano, G.
    Fumoleau, P.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (04) : 871 - 879
  • [40] A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines
    Schmid, P.
    Kuehnhardt, D.
    Kiewe, P.
    Lehenbauer-Dehm, S.
    Schippinger, W.
    Greil, R.
    Lange, W.
    Preiss, J.
    Niederle, N.
    Brossart, P.
    Freier, W.
    Kuemmel, S.
    de Velde, H. Van
    Regierer, A.
    Possinger, K.
    ANNALS OF ONCOLOGY, 2008, 19 (05) : 871 - 876
12345